Herpes simplex virus type 1 (HSV-1) produces oral lesions, encephalitis, keratitis, and severe infections in the immunocompromised host. HSV-1 is almost as common as HSV-2 in causing first episodes of genital herpes, a disease that is associated with an increased risk of human immunodeficiency virus acquisition and transmission. No approved vaccines are currently available to protect against HSV-1 or HSV-2 infection. We developed a novel HSV vaccine strategy that uses a replication-competent strain of HSV-1, NS-gEnull, which has a defect in anterograde and retrograde directional spread and cell-to-cell spread. Following scratch inoculation on the mouse flank, NS-gEnull replicated at the site of inoculation without causing disease. Importantly, the vaccine strain was not isolated from dorsal root ganglia (DRG). We used the flank model to challenge vaccinated mice and demonstrated that NS-gEnull was highly protective against wild-type HSV-1. The challenge virus replicated to low titers at the site of inoculation; therefore, the vaccine strain did not provide sterilizing immunity. Nevertheless, challenge by HSV-1 or HSV-2 resulted in less-severe disease at the inoculation site, and vaccinated mice were totally protected against zosteriform disease and death. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice. The vaccine provided protection against disease and death after intravaginal challenge and markedly lowered the titers of the challenge virus in the vagina. Therefore, the HSV-1 gEnull strain is an excellent candidate for further vaccine development.
Herpes simplex virus type 1 (HSV-1) and HSV-2 are closely related alphaherpesviruses that cause lifelong infections for which there is no cure. HSV-1 generally causes oral lesions, while HSV-2 remains the most common cause of genital ulcers; however, the epidemiology of genital herpes is changing in that 35% to 50% of new cases are now caused by HSV-1 (40) . The life cycles of HSV-1 and HSV-2 are similar. After replication in epithelial cells, HSV enters local sensory nerve endings of the peripheral nervous system and spreads in a retrograde direction to neuronal cell bodies. HSV then spreads to adjacent neurons in ganglia, where a lifelong latent infection is established (43) . During recurrences, HSV travels in the anterograde direction along axon fibers from infected neuronal cell bodies to skin or mucosal surfaces, resulting in asymptomatic virus shedding or symptomatic vesicles and ulcers.
More than 70% of people in the United States are seropositive for HSV-1 or HSV-2 by age 49, with HSV-1 being more prevalent (44) . Worldwide, the prevalence of infection is generally higher than in the United States (34) . Complications of HSV infection include meningitis, encephalitis, esophagitis, disseminated disease in neonates and immunocompromised individuals, and herpes stromal keratitis, which can lead to blindness. Additionally, HSV-2 infection increases human immunodeficiency virus (HIV) acquisition and transmission rates more than twofold, enhances HIV replication, and speeds progression to AIDS (7, 18, 37) . Despite the significant morbidity and mortality associated with HSV infections, no effective vaccines are available.
Efforts to develop HSV vaccines have included inactivated whole-virus vaccines, subunit glycoprotein preparations, DNA plasmids, and live attenuated viruses (32, 35) . The vaccine farthest along in human trials is a subunit glycoprotein vaccine developed by GlaxoSmithKline that uses HSV-2 glycoprotein D (gD) as an immunogen with alum and 2-O-deacylated monophosphoryl lipid A as adjuvants (4) . In two large, placebo-controlled clinical trials, women who were seronegative for both HSV-1 and HSV-2 were protected against genital ulcer disease. However, no significant protection was detected against infection, as measured by seroconversion, and the vaccine failed to protect men or HSV-1-seropositive women (36) .
A precedent exists for developing live virus vaccines for alphaherpesviruses, since a modified live virus vaccine is commercially available to prevent pseudorabies virus in pigs 3 days old or older (Schering-Plough Animal Health Corp.), and an attenuated live varicella-zoster virus vaccine is available for the prevention of chickenpox and shingles (31, 39) . In this study, we used an HSV-1 gE deletion strain, NS-gEnull, as a live attenuated vaccine. This strain has a large deletion within the gE gene (U S 8) and fails to express a functional gE protein (29) . Previous studies using NS-gEnull demonstrated that HSV-1 gE is required for efficient cell-to-cell spread in polarized epithelial cells; anterograde transport of viral capsid, tegument, and glycoproteins from the neuron cell body to the axon terminus; and the spread of virus in the retrograde direction from epithelial cells to neuronal cell bodies in dorsal root ganglia (DRG) (11, 33, 41) . This result differs from that seen with pseudorabies virus gE, which is required for anterograde but not retrograde spread (6, 8) . The NS-gEnull impairment in retrograde spread is an important safety feature for the vaccine, since this strain has reduced capacity for reaching DRG, the site of latency. The anterograde-spread defect of the virus is an added safety feature in that even if limited quantities of vaccine virus reach the DRG by retrograde spread, anterograde transport should not occur back to the skin or mucosa to cause recurrent infections.
In this study, we used the mouse flank model to evaluate the safety and efficacy of the NS-gEnull vaccine. The results demonstrated that after flank scarification, the vaccine strain did not cause lesions and no virus was recovered from DRG. Upon challenge with wild-type HSV-1, vaccinated mice were completely protected against zosteriform disease and death, and virus was not reactivated from DRG by explant coculture in Ͼ90% of mice. The NS-gEnull vaccine candidate also protected against HSV-1 challenge intravaginally and provided cross-protection against HSV-2 after flank challenge. Therefore, NS-gEnull has excellent potential for development as a replication-competent, attenuated live virus vaccine.
MATERIALS AND METHODS
Virus strains. HSV-1(NS) was isolated from the respiratory tract of a child and was used as a low-passage-number wild-type virus for challenge experiments (15) . NS-gEnull has a deletion within the region of the U S 8 gene encoding gE amino acids 124 to 512, while a repaired virus, rNS-gEnull, restores this region and gE functions (29) . Other HSV-1 strains included KOS (321), F, and 17. HSV-2(2.12) is a low-passage-number isolate obtained from a genital lesion of an 18-year-old woman (19) . All viruses were grown and titered on Vero cells using Dulbecco's modified Eagle medium (DMEM) and 5% fetal bovine serum (FBS).
Growth curves. Vero cells grown in 12-well dishes were infected at a multiplicity of infection of 5 with NS, NS-gEnull, or rNS-gEnull. In some wells, the inoculum was collected immediately after it was placed on the cells as the zero-hour time point. In other wells, virus was adsorbed for 1 h at 37°C, the inoculum was removed, and cells were washed once with citrate buffer (pH 3.0) to inactivate virus that had not yet entered cells and twice with DMEM containing 5% FBS (1). Cells and supernatant fluids were harvested at this time point, which was considered 1 h postinfection, and at 2, 4, 8, 24, and 30 h. Cells and supernatant fluids were frozen at Ϫ80°C and were later thawed, sonicated, and titered on Vero cells.
Murine vaccinations. Vaccinations were performed on 6-to 8-week-old female BALB/c mice (National Cancer Institute). Mice were anesthetized prior to all procedures by using 100 l xylazine (14.3 mg/ml) (Vedco, Inc.) and ketamine (1.8 mg/ml) (Hospira, Inc.) in phosphate-buffered saline (PBS). Mice were vaccinated either by flank scarification, subcutaneously (SubQ) in the neck scruff, or intramuscularly (i.m.) in the right rear thigh. Fifty microliters of inoculum was used for SubQ and i.m. vaccinations, while for flank scarification, hair was first removed on the right flank by shaving and applying Nair. The following day, 10 l containing NS-gEnull was placed on the denuded flank and inoculated using a 26 5/8-gauge needle to make 60 gentle scratches, each approximately 5 mm in length (23) . Mock-vaccinated animals were scratch inoculated with an equivalent volume of uninfected cell lysate in DMEM with 5% FBS. Mice were scored for lesion severity at both the inoculation and zosteriform sites. Inoculation site disease was scored as 0 for no disease, 1 for redness or swelling, 2 for skin erosions, 3 for ulcers, and 4 for necrosis. Lesions outside the zone of inoculation were considered zosteriform disease, which was scored as 0 for no lesions, 1 for one or more discrete lesions, 2 for coalesced lesions, 3 for ulcerated lesions, and 4 for necrosis.
Murine challenge experiments. Flank challenge was performed at least 28 days after vaccination by scarification on the flank opposite the one used for immunization. For vaginal challenge, mice received a SubQ injection of 2 mg of medroxyprogesterone (Sicor Pharmaceuticals, Inc., Irvine, CA) in 0.9% NaCl-10 mM HEPES 23 days after flank vaccination (21) . Mice were challenged 5 days later with 10 5 PFU HSV-1(NS) in 5 l by vaginal instillation. Vaginal specimens were collected daily using dry calcium alginate swabs. The swab tips were cut off and placed in 0.5 ml DMEM with 5% FBS; then they were vortexed and frozen at Ϫ80°C until titration on Vero cells.
Titration of virus in tissue. Mice were euthanized prior to removal of DRG and skin at the inoculation site. DRG samples were minced with small scissors and pulverized using a pestle, and half the sample was titered on Vero cells. The remainder of the DRG sample was evaluated by real-time quantitative PCR (RT qPCR). Skin samples were divided in half. One part was processed using scissors and a pestle and was titered on Vero cells. The other part of the skin sample was processed for immunohistochemistry.
Immunohistochemistry. Skin samples were placed in 4% paraformaldehyde in PBS for 24 h and transferred to PBS until they were paraffin embedded and sectioned. The Pathology Core Facility at the Children's Hospital of Philadelphia processed the tissue samples, which were stained sequentially for 30 min at room temperature with polyclonal anti-HSV-1 immunoglobulin G (IgG) (1:1,500; Dako), biotinylated anti-rabbit IgG (1:200; Vector Laboratories), and avidinbiotin (1:200) and were then counterstained with hematoxylin.
RT qPCR. Each sample was amplified for HSV-1 U S 9 DNA and mouse adipsin DNA. PCRs were performed in 96-well qPCR dishes using 2ϫ FAST Taqman master mix (Applied Biosystems). The primers for detection of U S 9 DNA were as follows: forward, 5Ј-ACGGCCTCGCCAGTTTC-3Ј (melting temperature [T m ], 58°C); reverse, 5Ј-TTGGCCGCCTCGTCTTC-3Ј (T m , 59°C). The primers for detection of murine adipsin DNA were as follows: forward, 5Ј-GCAGTCG AAGGTGTGGTTACG-3Ј (T m , 59°C); reverse, 5Ј-GGTATAGACGCCCGGC TTTT-3Ј (T m , 59°C). The probes were 5Ј-TCGAAGCCTACTACTCG-3Ј (T m , 70°C) for U S 9 and 5Ј-CTGTGGCAATGGC-3Ј (T m , 70°C) for adipsin. The reporter dye was 6-carboxyfluorescein (5Ј), while BHQ (3Ј) was used as the quencher. All reactions were carried out in a FAST 7500 qPCR machine (Applied Biosystems). Standard curves were derived using 5 to 10 7 copies of HSV-1 DNA and 5 to 10 5 copies of murine cellular DNA (Biochain, Hayward, CA). RT qPCR results were expressed as the HSV-1 DNA copy number per 5 ϫ 10 5 copies of murine adipsin.
Explant cocultures of DRG for recovery of latent HSV-1. At least 28 days after challenge, mice were sacrificed, and the DRG were removed, minced with scissors, and placed on Vero cells in DMEM containing 5% FBS supplemented with 25 g/ml vancomycin (38) . Cultures were observed for virus reactivation for 20 days.
Neutralization assays. Serum was obtained from mice by the submandibular route using the Goldenrod animal lancet (Medipoint, Inc.) 21 days after vaccination. The serum was heat inactivated for 30 min at 56°C and then diluted 1:10 to 1:320 in DMEM containing 10% FBS, and 50 l was added to an equal volume containing 100 PFU of HSV-1(NS). After 1 h at 37°C, 300 l of DMEM containing 10% FBS was added, and 200 l was inoculated onto duplicate wells of Vero cells in 12-well tissue culture dishes. Plates were incubated for 1 h at 37°C with gentle rocking every 10 min. The inoculum was removed; cells were washed twice with PBS, overlaid with medium containing 0.6% agarose, and incubated for 72 h at 37°C; and plaques were counted (17) .
Statistics. The mean and standard error of the mean (SEM) were calculated for each data point. P values were calculated using GraphPad Prism software. Statistical tests were t tests except that the data in Fig. 1C , 2C, 4C, and 5C were analyzed using a Kruskal-Wallis test, and we used analysis of variance with Tukey's adjustment, which allows for all possible pairwise comparisons, for Fig.  1B , 2B, 4B, and 5B. Survival curves were analyzed using the log rank (MantelCox) test.
RESULTS

Safety of HSV-1 NS-gEnull as a vaccine in mice.
A mouse flank scarification model was used to evaluate the safety of the NS-gEnull live virus vaccine candidate. Comparisons included the repaired virus, rNS-gEnull, and mock scarification, which served as a control for lesions produced during the scratch immunization. All mice survived after NS-gEnull infection at 5 ϫ 10 5 PFU; however, only 20% survived after infection with rNS-gEnull (Fig. 1A) . rNS-gEnull caused severe lesions at the inoculation site, while NS-gEnull disease was indistinguishable from that with mock scarification (Fig. 1B) . Zosteriform disease develops when virus spreads from the DRG back to the skin. rNS-gEnull caused severe zosteriform disease (Fig. 1C) , appearing as a necrotic band spanning the entire right flank. No zosteriform lesions were seen in mice inoculated with NSgEnull.
rNS-gEnull grew to high titers in the skin, while only low titers of NS-gEnull were isolated (Fig. 1D) . The skin titer results were corroborated by immunohistochemistry in that viral antigens were readily detected on day 3 following infection with HSV-1(NS) while only scant antigen was noted with NS-gEnull (Fig. 1E) . Importantly, NS-gEnull was not recovered from DRG on day 1, 3, 6, or 8 postinfection (Fig. 1F) . In contrast, rNS-gEnull was isolated from DRG, reaching titers of 10 4 PFU on day 3. Additionally, no NS-gEnull was recovered from explant cocultures of right and left sacral ganglia performed 1 year after the vaccination of five mice with 5 ϫ 10 5 PFU of NS-gEnull (data not shown). NS-gEnull replicated comparably to wild-type and rescued strains in single-step growth curves performed in Vero cells (Fig. 1G) , indicating that reduced skin and DRG titers were not caused by defective replication. 5 copies of adipsin within the DRG of challenged mice (P ϭ 0.03 on day 3; P ϭ 0.02 on day 6; P ϭ 0.4 on day 8). The asterisk indicates the average log 10 copy number including an outlier of 10 4 PFU, possibly due to contamination, on day 1 (P ϭ 0.48 with the day 1 outlier; P ϭ 0.42 without the outlier). There were three mice in each group. Data points in panels B, C, D, F, and G are means Ϯ SEMs. LOD refers to the limit of detection for the assay, which was 20 PFU.
inoculation site (Fig. 2B) . The mock-vaccinated animals developed ulcers, whereas the inoculation site disease of the vaccinated mice healed rapidly. All mock-vaccinated mice developed severe zosteriform disease, while none of the NS-gEnull-vaccinated mice developed zosteriform lesions (Fig. 2C) .
Viral skin titers at the inoculation site and DRG titers were determined after challenge of mock-vaccinated mice or mice vaccinated with 5 ϫ 10 5 PFU of NS-gEnull. Titers of NSgEnull-vaccinated mice were below the limit of detection for the assay (20 PFU), while 10 6 PFU was detected in mockvaccinated mice (Fig. 2D) . Immunohistochemistry revealed only trace amounts of viral antigen in NS-gEnull-vaccinated mice on days 3 and 6 postchallenge, compared with abundant antigen in mock-vaccinated mice (Fig. 2E) . DRG viral titers reached 10 4 PFU in mock-vaccinated mice on day 3 postchallenge, while no virus was recovered from the DRG of vaccinated mice (Fig. 2F) . RT qPCR of viral genomes in the DRG demonstrated differences of 3 to 4 log 10 copies of HSV DNA between mock-and NS-gEnull-vaccinated mice on days 3 and 6 postchallenge (Fig. 2G) . Therefore, no infectious virus was recovered from DRG after the challenge of NS-gEnull-vaccinated mice; levels of viral DNA in DRG were greatly reduced; and animals were totally protected from zosteriform disease and death.
Additional challenge studies were performed using HSV-1(NS) at doses of 10 6 and 10 7 PFU. Mice vaccinated with 5 ϫ 10 5 PFU of NS-gEnull were protected from severe inoculation site disease, zosteriform lesions, and death, even after challenge at these higher doses (data not shown).
NS-gEnull vaccination reduces the recovery of latent challenge virus from DRG explants. We evaluated whether the vaccine protects the DRG of mice from infection as assessed by virus reactivation from explant cocultures. Mice were either mock vaccinated or vaccinated with 5 ϫ 10 5 PFU of NS-gEnull by flank scarification. Twenty-eight days later, mice were challenged with 10 5 PFU of HSV-1(KOS) by scarification of the opposite flank. Strain KOS was used because it does not kill mice at this dose after flank inoculation; therefore, mockimmunized mice survived, permitting evaluation of DRG for recovery of latent virus.
KOS produced severe inoculation and zosteriform site disease in mock-immunized mice, while challenge of NS-gEnullvaccinated mice produced less inoculation site disease and no zosteriform disease (Fig. 3A and B) . Virus was reactivated from explant cultures of all 10 DRG from mock-vaccinated mice, while only 1 of 10 DRG from NS-gEnull-vaccinated mice yielded virus after challenge (Fig. 3C) . Therefore, the vaccine protected 90% of the mice from latent DRG infection after KOS challenge, as evaluated by explant cocultures.
NS-gEnull vaccination is effective when administered i.m. or SubQ. The effectiveness of NS-gEnull vaccination with 5 ϫ 10 5 PFU was compared using epidermal scarification, the i.m. route, or the SubQ route. Control mice were vaccinated by mock epidermal scarification. Twenty-eight days later, mice were challenged on the right flank using 10 5 PFU HSV-1(NS). All mice vaccinated with NS-gEnull survived the challenge regardless of the route of vaccination, while 20% of mockvaccinated animals survived (Fig. 4A ). Mice vaccinated with NS-gEnull by any route developed only mild inoculation site disease, which healed rapidly (Fig. 4B) . Mock-vaccinated mice developed severe zosteriform disease, while mice vaccinated by the i.m. or epidermal route were completely protected from zosteriform disease. One of five mice vaccinated SubQ had mild zosteriform disease (Fig. 4C) .
Explant cocultures were performed on DRG to monitor for reactivation of infection 28 days following challenge. A single mock-vaccinated survivor served as a positive control (Fig.  4D) . All mice vaccinated with NS-gEnull i.m. or by scarifica- Mice were monitored for inoculation site disease (P ϭ 0.03) and zosteriform disease (P ϭ 0.04 on day 5; P Ͻ 0.001 on days 6 and 7). The data points are means Ϯ SEMs. (C) DRG explant cocultures were performed 28 days after challenge (P Ͻ 0.001). There were 10 mice in each group.
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on October 2, 2017 by guest http://jvi.asm.org/ tion failed to reactivate virus from DRG explant cocultures; however, the DRG from one of five mice vaccinated SubQ reactivated the virus. Antibody neutralization titers were evaluated 3 weeks postimmunization. Neutralizing antibody titers induced by i.m. or epidermal scarification vaccination were more robust than those for the SubQ route (Fig. 4E) ; however, all immunization methods were protective.
NS-gEnull vaccination protects against epidermal challenge with heterologous HSV-1 strains. In experiments shown in Fig.  1 to 3 , protection provided by NS-gEnull immunization was determined by challenge with the same strain that was used to produce the vaccine virus, or with a less virulent HSV-1 strain, KOS. We next evaluated protection using two additional HSV-1 strains, F and 17. Mice were vaccinated with 5 ϫ 10 5 PFU of NS-gEnull by epidermal scarification and were challenged 28 days later by epidermal scarification on the opposite flank with 10 5 PFU of HSV-1(NS), HSV-1(F), or HSV-1 (17) . All the NS-gEnull-vaccinated mice survived, while the survival of mock-vaccinated mice was 25% (1 of 4) for strain NS, 33% (1 of 3) for strain F, and 67% (2 of 3) for strain 17 (Fig. 5A) .
The challenge viruses caused inoculation site disease in vaccinated mice that was more severe than that produced by the scratch alone but less severe than that in mock-vaccinated mice (Fig. 5B) . Vaccinated mice were completely protected from zosteriform disease caused by strain 17 or NS, while one of three vaccinated mice challenged with strain F developed mild zosteriform disease on day 5 that healed by day 7 (Fig. 5C) .
NS-gEnull vaccination cross-protects against HSV-2 challenge. Mice were either mock vaccinated or vaccinated with 5 ϫ scarification on the opposite flank. All vaccinated mice survived, while only 20% of mock-vaccinated mice survived (Fig.  6A) . Vaccinated mice developed disease at the inoculation site; however, the lesions healed more rapidly than those in mock-vaccinated mice (Fig. 6B ). All mock-vaccinated mice developed severe zosteriform disease, while none of the NSgEnull-vaccinated mice developed zosteriform lesions (Fig.  6C ). One year following challenge, DRG were evaluated for latent virus by explant cocultures from the four vaccinated mice and the one surviving mock-vaccinated mouse. The DRG from the mock-vaccinated mouse reactivated the virus, while no virus was recovered from the DRG of NS-gEnull-vaccinated mice (Fig. 6D) . Therefore, NS-gEnull cross-protected mice against HSV-2 challenge. NS-gEnull vaccination protects against vaginal HSV-1 challenge. The flank model is useful as a surrogate for epidermal infection of the male genitalia. To evaluate the protection provided by NS-gEnull scarification against mucosal challenge, mice were either mock vaccinated or vaccinated with 5 ϫ 10 5 PFU of NS-gEnull by epidermal scarification, and 28 days later, they were challenged by vaginal infection with 10 5 PFU of HSV-1(NS). All mice vaccinated with NS-gEnull survived, while only 40% of mock-vaccinated mice survived (Fig. 7A) . Vaginal titers on day 1 in vaccinated mice were 2 log 10 units lower than those in mock-vaccinated mice, and by day 2, titers were approximately 3 log 10 units lower. By day 3, titers were undetectable in NS-gEnull-vaccinated mice, while titers remained positive until day 8 in mock-vaccinated mice (Fig. 7B) . All mock-vaccinated mice showed signs of vaginal disease, but none of the NS-gEnull-vaccinated mice had disease (Fig. 7C) . Therefore, NS-gEnull vaccination protected mice against disease and death after vaginal HSV-1 challenge and accelerated the time to clearance of the challenge virus from the vagina.
DISCUSSION
We described a live virus vaccine candidate using NS-gEnull, a gE-defective strain that is replication competent but impaired in anterograde and retrograde spread and cell-to-cell spread (33, 41 ). An important indicator of an effective HSV vaccine is the ability to prevent recurrences by protecting the DRG from infection. Since spontaneous recurrences do not occur in mice, we used DRG explant cocultures as a surrogate for recurrences. Our results demonstrated that NS-gEnull was both safe and effective in mice, since it produced no observable disease and greatly reduced the recovery of latent challenge virus from DRG explant cultures.
Other HSV-1 live-virus vaccines have been evaluated in animal models, including a strain defective in ␥34.5, a neurovirulence gene, and mutants R7017 and R7020. HSV-1 ␥34.5 mutant 1716 protected mice in a zosteriform model from skin disease and death; however, protection of ganglia was not reported (27) . This mutant strain is currently under evaluation as a gene therapy vector for brain tumors but not as a vaccine neal infection model (25) . Although the vaccine strains were safe when tested in owl monkeys, R7020 was poorly immunogenic in phase I human clinical trials, a result that is perhaps attributable to impaired inoculation site replication of this strain (26, 35) .
An HSV-2 gH pseudotype virus, referred to as a disabled infectious single-cycle (DISC) virus, has been evaluated as a live-virus vaccine (10) . The gene encoding gH was deleted, and the mutant strain was grown on gH-complementing cells. The vaccine virus is capable of only a single round of replication, since gH is required for virus entry. In humans, the DISC vaccine induced humoral and cellular immunity but failed to modify recurrence rates when used as a therapeutic vaccine in subjects with genital herpes.
HSV-2 dl5-29 is a replication-defective live-virus vaccine candidate containing deletions in the helicase-primase complex (U L 5) and single-stranded DNA binding protein (U L 29) genes (9) . This vaccine protected guinea pigs in a vaginal challenge model, leading to lower viral titers during acute infection, Ͼ10-fold reduction of latent viral DNA loads, and fewer recurrences (20) . Protection was similar to that provided by an HSV-2 gD subunit vaccine; however, the live-virus vaccine induced higher titers of neutralizing antibodies and a more robust HSV-2-specific CD8 ϩ T-cell response. NS-gEnull is replication competent; however, the vaccine strain is impaired in cell-to-cell spread, as evidenced by its small plaque phenotype (33) . This spread defect likely contributes to the limited disease, to the low virus titers detected at the skin inoculation site, and to reduced infection of DRG. Despite the spread defect, NS-gEnull replication at the inoculation site is sufficient to induce neutralizing antibodies and protect against challenge by virulent HSV-1 and HSV-2 strains. This strain also has an anterograde-spread defect that likely will reduce the risk of recurrent skin or mucosal lesions and person-to-person transmission if it is used as a human vaccine.
HSV-1(F) challenge at 10 5 PFU resulted in breakthrough zosteriform lesions, although few in number, while NS challenge at 10 7 PFU failed to produce zosteriform lesions. These results suggest that protection is more effective against the strain used to produce the vaccine than against other HSV-1 isolates. We made no adjustments to administer identical 50% lethal doses (LD 50 ) in the challenge experiments; however, for the small number of animals evaluated, survival was comparable in mock-immunized mice challenged with 10 5 PFU of strain NS, F, or 17 (25%, 33%, and 67%, respectively), suggesting little variation in the LD 50 for these three virus strains. Future studies will need to evaluate the protection provided by the vaccine strain against a wider range of isolates challenged at comparable LD 50 .
Viral DNA was detected in the DRG by RT qPCR following challenge of vaccinated mice; however, no infectious virus was detected by DRG cultures. The RT qPCR does not distinguish the vaccine virus from the challenge virus, since both viruses contain the U S 9 region used for amplification. The DRG were harvested from the right side of the body, which was the side of the challenge and opposite the side used for vaccination, suggesting that the viral DNA detected was more likely the challenge strain than the vaccine strain. DRG DNA levels in vaccinated mice did not increase from day 1 to day 8 postchallenge, suggesting that much of the DNA was noninfectious; however, explant cultures 28 days or later after challenge were positive for HSV-1 in 2/24 (8%) mice, suggesting that the challenge virus reached the DRG and established latency in some mice.
HSV-1 gE functions as an immune evasion molecule that interacts with gI to form a high-affinity Fc␥ receptor that binds the Fc domain of human IgG and blocks Fc-mediated events, such as complement activation and antibody-dependent cellular cytotoxicity (3, 12) . HSV-1 NS-gEnull lacks this immune evasion potential, which, in addition to its inability to spread, is another safety feature of the vaccine strain. Deletion of gE results in the loss of this glycoprotein as an immunogen; however, studies that assessed the immunization properties of gE indicated that this glycoprotein provides only modest protection against challenge when used alone (5, 16, 28, 30) .
A recent report compared HSV-1 gD subunit and DNA vaccines with a live-virus preparation, ANGpath/gE3-3 (13). This mutant virus is both gE null and syncytial because of a mutation in gB (42) . Protection by the live virus and the gD DNA preparations were comparable in a murine intraperitoneal challenge model, and both were superior to the gD glycoprotein vaccine. The results with the ANGpath/gE3-3 strain are consistent with our findings that a gE deletion mutant virus is highly protective in a murine model.
The GlaxoSmithKline HSV-2 gD subunit human vaccine trial showed partial protection in seronegative women but no protection in HSV-1-seropositive women or men (36) . The gender difference in protection remains unexplained, since vaccines for other pathogens have not shown gender specificity. Studies that evaluate protection by the human papillomavirus vaccine in men and women will help clarify whether males are less readily protected against sexually transmitted infections than women (2) . Perhaps the gender disparity in protection is related to differences between mucosal and epidermal immunity (14) . The vagina is comprised of nonkeratinized mucosal epithelial cells, while the penis contains keratinized epidermal cells. Cellular and humoral immune components may infiltrate into mucosal vaginal tissues more readily than into keratinized skin. The mouse flank scarification challenge more closely mimics male genital infection, while the mouse vaginal challenge resembles infection of the human female genital tract. We were encouraged that NS-gEnull protected mice in both epidermal and vaginal challenge models.
More information is available about the molecular pathogenesis of HSV-1 than about that of HSV-2, although vaccine efforts to date have focused largely on prevention of HSV-2 infection. NS-gEnull vaccination of mice provided substantial protection against disease following HSV-2 challenge. Epidemiologic studies of humans indicate that subjects previously infected with HSV-1 remain at least partially susceptible to HSV-2; therefore, we expect that protection against HSV-2 will require a vaccine prepared in an HSV-2 background (22) . HSV-2 gE shares 73% amino acid identity with HSV-1, suggesting that a similar approach using HSV-2 gEnull as a vaccine candidate may be effective. An HSV-1 vaccine is worth pursuing even if a separate HSV-2 vaccine is also required, since encephalitis, keratitis, VOL. 82, 2008 HSV-1 NS-gEnull AS A LIVE ATTENUATED VACCINE 8439
on October 2, 2017 by guest http://jvi.asm.org/ and many newly acquired genital herpes infections are attributed to HSV-1 (40) . An effective HSV-1 live-virus vaccine may reduce the incidence of multiple serious diseases, including some cases of genital ulcer disease, thereby reducing the rates of HIV acquisition and transmission (37) .
